|Previous Section||Index||Home Page|
|Percentage immunised with MMR (1 dose) by age:||Percentage immunised with MMR ( 1st and 2nd dose) by age:||Percentage immunised with MMR (1 dose) by age:||Percentage immunised with MMR ( 1st and 2nd dose) by age:|
|PCT code||PCT name||2 yrs||5 yrs||5 yrs||2 yrs||5 yrs||5 yrs|
Some PCTs were not able to provide figures due to problems relating to implementation of new Child Health Systems.
Mike Penning: To ask the Secretary of State for Health with reference to the answer to the hon. Member for Billericay of 5 November 2009, Official Report, column 1168W, on drugs, when he expects to receive the report from Professor Sir Mike Richards; and whether he plans to publish the findings of that investigation before April 2010. 
Mr. Hoyle: To ask the Secretary of State for Health (1) if he will issue guidance on liability in cases where a drug automatically generically substituted by a pharmacist adversely affects a patient and that patient's GP has not informed the pharmacist that such adverse effects are likely; 
(2) what assessment has been made of the effect of implementation of proposals for automatic generic substitution of medicines on the workload of (a) clinicians, (b) pharmacists, (c) nurse prescribers and (d) other health professionals; and if he will make a statement. 
Mr. Mike O'Brien: In developing the proposals and analysis set out in the consultation document "The proposals to implement 'Generic Substitution' in primary care, further to the Pharmaceutical Price Regulation Scheme (PPRS) 2009" and its associated partial impact assessment, published on 5 January 2010, the Department was informed by information from stakeholders, including concerns relating to liability. Under the Department's preferred approach (option 3), there are mechanisms for ensuring that patients continue to receive the most appropriate treatment.
Therefore, we believe the liability risks associated with the proposed generic substitution arrangements should not be any greater than under current prescribing and dispensing arrangements. The Department has not issued guidance on liability for prescribing and does not anticipate that such a need will arise under the generic substitution arrangements.
We recognise that further evidence may be available in relation to both liability and impact on health professionals' workload, which is why we are holding a full public consultation, to which all those with an interest can input, including patients. The consultation document and partial impact assessment can be found on the Department's website at:
|Next Section||Index||Home Page|